Pulse Biosciences Q4 GAAP net loss widens to $19.4M; cash boosted to $118M on warrant exercises

PULSE BIOSCIENCES, INC.

GAAP net loss of $19.4M in Q4 2024 vs $11.9M a year ago; full-year loss $53.6M vs $42.2M.
Cash and equivalents $118.0M as of Dec 31, 2024, up from $44.4M a year ago, driven by $47.9M in warrant proceeds.
Non-GAAP net loss Q4 $10.4M vs $8.3M; full-year $36.9M vs $33.8M; costs rose on stock comp and legal settlement.
Advanced soft tissue ablation pilot at 8 U.S. centers; expects U.S. thyroid clinical trial mid-2025.
Treated 30 patients in European AF feasibility study for surgical clamp; over 80 patients in catheter study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.